Richard Pötter1, Mario Federico2, Alina Sturdza3, Irina Fotina4, Neamat Hegazy5, Maximilian Schmid1, Christian Kirisits1, Nicole Nesvacil6. 1. Department of Radiotherapy, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna, Austria. 2. Department of Radiotherapy, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Radiation Oncology, Gran Canaria University Hospital, Las Palmas de Gran Canaria, Spain. 3. Department of Radiotherapy, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria. 4. Department of Radiotherapy, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Institute of Physics and Technology, Tomsk Polytechnic University, Tomsk Oblast, Russia. 5. Department of Radiotherapy, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Clinical Oncology, Medical University of Alexandria, Alexandria, Egypt. 6. Department of Radiotherapy, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Christian Doppler Laboratory for Medical Radiation Research for Radiation Oncology, Medical University of Vienna, Vienna, Austria. Electronic address: nicole.nesvacil@meduniwien.ac.at.
Abstract
PURPOSE: To define, in the setting of cervical cancer, to what extent information from additional pretreatment magnetic resonance imaging (MRI) without the brachytherapy applicator improves conformity of CT-based high-risk clinical target volume (CTVHR) contours, compared with the MRI for various tumor stages (International Federation of Gynecology and Obstetrics [FIGO] stages I-IVA). METHODS AND MATERIALS: The CTVHR was contoured in 39 patients with cervical cancer (FIGO stages I-IVA) (1) on CT images based on clinical information (CTVHR-CTClinical) alone; and (2) using an additional MRI before brachytherapy, without the applicator (CTVHR-CTpre-BT MRI). The CT contours were compared with reference contours on MRI with the applicator in place (CTVHR-MRIref). Width, height, thickness, volumes, and topography were analyzed. RESULTS: The CT-MRIref differences hardly varied in stage I tumors (n=8). In limited-volume stage IIB and IIIB tumors (n=19), CTVHR-CTpre-BT MRI-MRIref volume differences (2.6 cm(3) [IIB], 7.3 cm(3) [IIIB]) were superior to CTVHR-CTClinical-MRIref (11.8 cm(3) [IIB], 22.9 cm(3) [IIIB]), owing to significant improvement of height and width (P<.05). In advanced disease (n=12), improved agreement with MR volume, width, and height was achieved for CTVHR-CTpre-BT MRI. In 5 of 12 cases, MRIref contours were partly missed on CT. CONCLUSIONS: Pre-BT MRI helps to define CTVHR before BT implantation appropriately, if only CT images with the applicator in place are available for BT planning. Significant improvement is achievable in limited-volume stage IIB and IIIB tumors. In more advanced disease (extensive IIB to IVA), improvement of conformity is possible but may be associated with geographic misses. Limited impact on precision of CTVHR-CT is expected in stage IB tumors.
PURPOSE: To define, in the setting of cervical cancer, to what extent information from additional pretreatment magnetic resonance imaging (MRI) without the brachytherapy applicator improves conformity of CT-based high-risk clinical target volume (CTVHR) contours, compared with the MRI for various tumor stages (International Federation of Gynecology and Obstetrics [FIGO] stages I-IVA). METHODS AND MATERIALS: The CTVHR was contoured in 39 patients with cervical cancer (FIGO stages I-IVA) (1) on CT images based on clinical information (CTVHR-CTClinical) alone; and (2) using an additional MRI before brachytherapy, without the applicator (CTVHR-CTpre-BT MRI). The CT contours were compared with reference contours on MRI with the applicator in place (CTVHR-MRIref). Width, height, thickness, volumes, and topography were analyzed. RESULTS: The CT-MRIref differences hardly varied in stage I tumors (n=8). In limited-volume stage IIB and IIIB tumors (n=19), CTVHR-CTpre-BT MRI-MRIref volume differences (2.6 cm(3) [IIB], 7.3 cm(3) [IIIB]) were superior to CTVHR-CTClinical-MRIref (11.8 cm(3) [IIB], 22.9 cm(3) [IIIB]), owing to significant improvement of height and width (P<.05). In advanced disease (n=12), improved agreement with MR volume, width, and height was achieved for CTVHR-CTpre-BT MRI. In 5 of 12 cases, MRIref contours were partly missed on CT. CONCLUSIONS: Pre-BT MRI helps to define CTVHR before BT implantation appropriately, if only CT images with the applicator in place are available for BT planning. Significant improvement is achievable in limited-volume stage IIB and IIIB tumors. In more advanced disease (extensive IIB to IVA), improvement of conformity is possible but may be associated with geographic misses. Limited impact on precision of CTVHR-CT is expected in stage IB tumors.
Authors: Katja Pinker; Piotr Andrzejewski; Pascal Baltzer; Stephan H Polanec; Alina Sturdza; Dietmar Georg; Thomas H Helbich; Georgios Karanikas; Christoph Grimm; Stephan Polterauer; Richard Poetter; Wolfgang Wadsak; Markus Mitterhauser; Petra Georg Journal: PLoS One Date: 2016-05-11 Impact factor: 3.240
Authors: Matthew M Harkenrider; Steven M Shea; Abbie M Wood; Bonnie Chinsky; Amishi Bajaj; Michael Mysz; Joseph H Yacoub; Ari Goldberg; Margaret Liotta; Ronald Potkul; Murat Surucu; John Roeske; William Small Journal: J Contemp Brachytherapy Date: 2017-03-30
Authors: Vonetta M Williams; Jenna M Kahn; Matthew M Harkenrider; Junzo Chino; Jonathan Chen; L Christine Fang; Emily F Dunn; Emma Fields; Jyoti S Mayadev; Ramesh Rengan; Daniel Petereit; Brandon A Dyer Journal: Brachytherapy Date: 2020-04-21 Impact factor: 2.362
Authors: Winnie Wing Ling Yip; Joyce Siu Yu Wong; Venus Wan Yan Lee; Frank Chi Sing Wong; Stewart Yuk Tung Journal: J Contemp Brachytherapy Date: 2017-10-30
Authors: Mario Federico; Carmen Rosa Hernandez-Socorro; Ivone Ribeiro; Jesus Gonzalez Martin; Maria Dolores Rey-Baltar Oramas; Marta Lloret Saez-Bravo; Pedro Carlos Lara Jimenez Journal: Radiat Oncol Date: 2019-10-04 Impact factor: 3.481